Developing treatments for pulmonary arterial hypertension

about

Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials

P2860

Q35552825-7A969CF0-FBF2-4E29-8E83-4A70E8541106

P2860

Developing treatments for pulmonary arterial hypertension

Item

http://www.wikidata.org/entity/Q38105549

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Developing treatments for pulmonary arterial hypertension

@en

type

Item

label

Developing treatments for pulmonary arterial hypertension

@en

prefLabel

Developing treatments for pulmonary arterial hypertension

@en

P1476

Developing treatments for pulmonary arterial hypertension

@en

P2093

Martin R Wilkins

http://www.w3.org/2001/XMLSchema#string

P2860

Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.

Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension.

Lung ¹⁸F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension

Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

Alterations of cellular bioenergetics in pulmonary artery endothelial cells

Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension.

Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.

Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by mo

Trial watch: Phase II failures: 2008-2010.

P304

156-159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/2045-8932.109961

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236676271

http://www.w3.org/2001/XMLSchema#string

P698

23662193

http://www.w3.org/2001/XMLSchema#string

P932

3641724

http://www.w3.org/2001/XMLSchema#string

Developing treatments for pulmonary arterial hypertension

about

P2860

P2860

Developing treatments for pulmonary arterial hypertension

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932